Cyfuse Biomedical K.K Past Earnings Performance
Past criteria checks 0/6
Cyfuse Biomedical K.K's earnings have been declining at an average annual rate of -39.2%, while the Life Sciences industry saw earnings growing at 28.2% annually. Revenues have been declining at an average rate of 42.7% per year.
Key information
-39.2%
Earnings growth rate
48.2%
EPS growth rate
| Life Sciences Industry Growth | 32.0% |
| Revenue growth rate | -42.7% |
| Return on equity | -18.4% |
| Net Margin | -965.6% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Cyfuse Biomedical K.K makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 61 | -589 | 351 | 375 |
| 30 Sep 23 | 63 | -735 | 421 | 303 |
| 30 Jun 23 | 60 | -723 | 411 | 303 |
| 31 Mar 23 | 215 | -584 | 368 | 303 |
| 31 Dec 22 | 374 | -473 | 346 | 303 |
| 31 Dec 21 | 708 | 142 | 500 | 0 |
| 31 Dec 20 | 137 | -329 | 439 | 0 |
Quality Earnings: 4892 is currently unprofitable.
Growing Profit Margin: 4892 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 4892's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 4892's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4892 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-19.3%).
Return on Equity
High ROE: 4892 has a negative Return on Equity (-18.39%), as it is currently unprofitable.